Advertisement
Screener

Neuronetics, Inc. (STIM) Overview

Neuronetics, Inc. (STIM) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.05; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.16; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.13; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.15; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$1.12$1.40$1.76$2.21$2.76$3.472025-11-062026-11-06$0.58$0.96$1.59$2.63$4.36$7.212021-11-082026-11-06$0.58$1.35$3.13$7.29$16.95$39.422018-06-282026-11-06$0.58$1.35$3.13$7.29$16.95$39.422018-06-282026-11-06$0.58$1.35$3.13$7.29$16.95$39.422018-06-282026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$2.15
Previous close
$2.36
Change
-$0.21
Change (%)
-9.11%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

STIM
+71.01%
S&P 500
(m)

1 year

STIM
-11.28%
S&P 500
(m)

3 years

STIM
+74.81%
S&P 500
(m)

5 years

STIM
-63.41%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.05

-0.29-0.18-0.080.030.1331 Mar 2025: estimate (m); actual -0.2131 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.1530 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.1330 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1631 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.05(m)(m)
1 Jan 202631 Mar 2026(m)-0.16(m)(m)
1 Jul 202530 Sept 2025(m)-0.13(m)(m)
1 Apr 202530 Jun 2025(m)-0.15(m)(m)
1 Jan 202531 Mar 2025(m)-0.21(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.59

-1.46-1.20-0.93-0.67-0.4131 Dec 2021: estimate (m); actual -1.2231 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.3831 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.0531 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.3831 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.5931 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.59(m)(m)
1 Jan 202431 Dec 2024(m)-1.38(m)(m)
1 Jan 202331 Dec 2023(m)-1.05(m)(m)
1 Jan 202231 Dec 2022(m)-1.38(m)(m)
1 Jan 202131 Dec 2021(m)-1.22(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 41.57M ■ Earnings -3.44M — Profit margin -8.27%

-17.10M-32.3%4.63M-24.0%26.36M-15.6%48.09M-7.3%30 Sept 2025: revenue 37.30M; earnings -9.04M; profit margin -24.25%30 Sept 202531 Dec 2025: revenue 41.78M*; earnings -7.16M*; profit margin -17.13%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 34.45M; earnings -10.79M; profit margin -31.32%31 Mar 202630 Jun 2026: revenue 41.57M; earnings -3.44M; profit margin -8.27%30 Jun 2026

31 Dec 2025 ■ Revenue 149.16M ■ Earnings -39.00M — Profit margin -26.15%

-66.85M-59.4%12.87M-48.0%92.58M-36.6%172.30M-25.1%31 Dec 2022: revenue 65.21M; earnings -37.16M; profit margin -56.99%31 Dec 202231 Dec 2023: revenue 71.35M; earnings -30.19M; profit margin -42.31%31 Dec 202331 Dec 2024: revenue 74.89M; earnings -43.71M; profit margin -58.36%31 Dec 202431 Dec 2025: revenue 149.16M; earnings -39.00M; profit margin -26.15%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$2.15(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$2.15High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning STIM

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-30.43M
Profit margin
-19.62%
Return on assets · 12 month
-22.87%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
658.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.30M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-18.90%*
Total return · month
-19.73%*
Total return · quarter
73.53%*
Total return · half year
82.95%*
Total return · year to date
71.01%*
Total return · 1 year
-11.28%*
Total return · 3 years
74.81%*
Total return · 5 years
-63.41%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$155.10M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Neuronetics, Inc. Overview

View more →

(m)

(m)

SEC CIK
1227636
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Country of operation
United States
Business address
3222 PHOENIXVILLE PIKE, MALVERN, Pennsylvania, 19355, United States
Fiscal year end
1231
Phone
877-600-7555

Similar stocks

Stock NameCountryMarket CapPE Ratio
Profound Medical Corp. (PROF)$0.206B-7.37
PRO DEX INC (PDEX)United States$0.234B13.64
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
Lucid Diagnostics Inc. (LUCD)United States$0.170B
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Cytosorbents Corp (CTSO)United States$0.274B-1.29
KORU Medical Systems, Inc. (KRMD)United States$0.151B-106.78
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92